Neumora Therapeutics, an Arch Venture Partners' investment leveraging ML to develop CNS drugs, emerged from stealth mode in 2021 with $500M in financing.
In 2020, Occam placed John Reynders, PhD, as the company's first Chief Data Sciences Officer. Prior to Neumora, John served as Vice President, data sciences, genomics and bioinformatics at Alexion, where he led the design, building and deployment of data sciences solutions spanning R&D, commercial, strategy and business development. Prior to joining Alexion, John served as the founding Chief Information Officer of Moderna Therapeutics.
